We are Median, and we are focused on improving the lives of patients through innovation

Oran Muduroglu is Chairman of the Board of Directors. Oran is a recognized leader in healthcare technology successfully building solutions that improve the quality of, and access to healthcare information. He has over 25 years of healthcare industry experience. Oran Muduroglu joined Verily 2017-2018, as Business Leader for the Health Platform activities of the company. Prior to joining Verily, Oran was the CEO of Medicalis, which was acquired by Siemens in 2017. Prior to joining Medicalis, Oran was the CEO of Health Informatics at Philips Medical Systems. Prior to joining Philips Medical Systems, he was the CEO of Stentor, a company he co-founded in 1998, which was acquired by Philips in 2005. In the early 1990s, he served as vice president of sales and marketing at Cemax, an early pioneer in image management and advanced visualization, and prior to that, he was a senior product manager at Toshiba Medical. Oran received his Bachelor of Science Hons, in Engineering, from King’s College London.

Fredrik Brag is Median’s Chief Executive and board member of Median Technologies. He founded the company in 2002, bringing years of technology company expertise gained in business development, fund raising and IPOs. He was previously Executive Vice President of HealthCenter / Focus Imaging, where he built significant experience in specialized medical imaging and information and communication technology. He graduated from the Stockholm School of Economics.

Jean-Christophe Montigny joined Median with over 25 years of executive committee experience in affiliates of large group and start-ups, in high growth and fast changing environments. Jean-Christophe was involved in the development and acceleration of Biophytis, as Chief Financial Officer, from 2009 to 2019, for which he steered the Euronext Growth listing as well as the NASDAQ listing preparation. Jean-Christophe holds an engineering degree from AgroParisTech and is a graduate of the Paris Institute of Political Studies (Sciences Po, Paris).

Nicolas Dano leads the Imaging CRO Business Unit, including operational delivery, commercial activities and R&D. He has over 25 years of experience in the healthcare industry in the field of innovation, technology and services where he developed strong skills in Strategy, Business Development, and development of Artificial Intelligence based Medical Devices.

Prior to joining Median Technologies, Nicolas was Senior Research Scientist at General Electric. He holds a Master of Science in Computer Vision, and an Executive MBA from HEC Paris.

As Chief Operating & Commercial Officer, Thomas Bonnefont leads the eyonis™ Business Unit from R&D to commercial strategy and market access. Before joining Median, Thomas was Global Commercial Vice-President at Guerbet Group where he built and expanded the Interventional Oncology franchise with a tremendous growth in the US, Europe and Asia-Pacific. Previously, Thomas held sales & marketing management positions within renowned organizations such as MicroPort, GE Healthcare, Laboratoires Pierre Fabre and Johnson & Johnson.

Chrystel Brun joined Median Technologies in 2023 as Chief Human Resource Officer to develop the company’s HR strategy and operational deployment in the company’s international and growth context. She brings to Median more than 20 years of experience in managing the human potential of high-growth international companies in complex and matrix environments. Prior to joining Median, Chrystel worked as a Global Shared Services Manager at Det Norske Veritas AS. In these different professional contexts, she contributed to increasing the performance of the teams by improving their working conditions and encouraging personal development, which are decisive factors for the economic success of any company. Chrystel is a true team leader, capable of making important decisions. To her, Human Resources is all about respecting the employees. Chrystel holds two master’s degrees, one in Finance and one in Human Resources Management.

Tim Haines is a Managing Partner at Abingworth. Tim has more than 25 years of international management experience in the life sciences industry in both public and private companies. During his time at Abingworth Tim has taken board roles in a number of companies including Astex, Fovea, Lombard Medical, MEDIAN Technologies, Pixium Vision, PowderMed, Proteon Therapeutics, Sientra and Stanmore Implants. Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for over five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Tim has a BSc from Exeter University and an MBA from INSEAD.

Kapil Dhingra founded and is the head of KAPital Consulting, a healthcare consulting firm. Dr. Dhingra also serves on several life science company boards, including Advanced Accelerator Applications, Exosome Diagnostics Inc., Autolus, and Five Prime, Inc.  He previously served on the Boards of several successful companies, including Biovex, Micromet, Algeta, and, YM Biosciences, that were acquired by major pharmaceutical companies. Prior to joining AAA, Dr. Dhingra worked for over 25 years in oncology clinical research and drug development. His experience includes nine years at Hoffman-La Roche, where he served in various positions, including Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development. Prior to that, he worked as a Senior Clinical Research Physician at Eli Lilly and Company.  Before joining industry, Dr. Dhingra was on the faculty of The University of Texas MD Anderson Cancer Center for 8 years where he pursued translational and clinical research career in addition to patient care responsibilities.  Dr. Dhingra specialized in internal medicine and medical oncology. He holds an MD (MBBS) degree from the All India Institute of Medical Sciences in New Delhi, India, with subsequent residency in internal medicine at Lincoln Medical and Mental Health Center in New York City, New York and New York Medical College in Valhalla, New York, and was a Fellow in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia.

Oern R. Stuge M.D, MBA, is an international executive with 30+ years of experience from the Life Science sector. He is currently Chairman of Orsco Lifesciences AG. Through this company, he holds several executive and non-executive board memberships and advisory roles. During the last 9 years, Dr. Stuge has participated in Enterprise Development of different companies and successfully sold/listed 7 of them: 5 of the portfolio companies have been successfully sold, following improved strategic positioning and operation, 2 of the portfolio companies have successfully launched their IPOs (Euronext Paris / ESM, Dublin, NASDAQ, Stockholm). Prior to founding ORSCO, Dr. Stuge worked for 12 years for Medtronic, Inc. in different roles including Senior Vice President (SVP) and President EMEA, Canada and Emerging Markets, and SVP and President Cardiac Surgery. He was a member of the Medtronic Executive Committee and Operating Committee. Dr. Stuge led a successful transformation of Medtronic’s global Cardiac Surgery business. Under his leadership, Medtronic founded the Structural Heart Division and launched the first commercially available percutaneous heart valve in the world. Prior to Medtronic, Oern held senior positions at Abbott Laboratories as well as at a Norwegian start up (CEO). Oern began his career as a practicing physician. He has an MD from the University of Oslo, and an MBA from IMD in Lausanne.

Ben McDonald is a Co-Founder, Partner, and Chief Investment Officer at Aegis Group Partners, a frontier technologies investment firm. He oversees Aegis Group Partners’ investments in a range of industries, including artificial intelligence, software, biotech, quantum computing, biomaterials, and clean tech.

Ben serves on the board of directors for Aegis Group Partners Holdco, Noble Biomaterials, SuperTurbo Technologies, and Next Generation Turbo. He also served on the board of directors of Introhive before its sale to Providence Strategic Growth. Prior to joining Aegis Group Partners, Ben was an investor at Citadel Global Equities and Ailanthus Capital Management, where he focused on the technology sector. He holds an MBA from the University of Cambridge and an HBA from Western University.